Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

Dementia Mortality Tied to Olive Oil Consumption

Higher olive oil intake was associated with a lower risk of dementia-related death in a large longitudinal study. The relationship remained significant after adjusting for

May 7, 2024

Multiple discoveries open new paths for early prediction of Parkinson’s disease trajectories

Hand tremors and slowed movements are two of the most widely recognized hallmarks of Parkinson’s disease, and for many sufferers the first indication that something

July 6, 2023

FDA approves Sarepta’s Duchenne gene therapy for nearly all patients

The Food and Drug Administration on Thursday approved Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy, for nearly all patients with the fatal muscle-wasting disease,

June 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.